One biopsy, one test, one report can lead to improved patient outcomes
PreciseDx™ delivers the power of one solution for simultaneous DNA and RNA analysis, providing a comprehensive view of genomic alterations and gene expression changes in cancer. With broad coverage of cancer types, this panel is designed to shorten the duration of treatment decision-making, empowering you to make informed and confident decisions for your patients.
01
Detect Multiple Biomarkers in a Single Assay
CGP can detect biomarkers at nucleotide-level resolution and typically comprises all major genomic variant classes (SNVs, indels, CNVs, fusions, splice variants), and large genomic signatures (TMB, MSI), maximizing the ability to find clinically actionable alterations.
02
Consolidate Testing to Save Time and Precious Samples
CGP consolidates biomarker detection into a single multiplex assay, eliminating the need for sequential testing. With a single test, you can assess the most prevalent as well as rare biomarkers. It limits the input of precious biopsy samples, and may reduce the risks and cost associated with rebiopsy.
03
Identify Actionable Alterations
CGP helps to identify more effective therapeutic paths and innovative clinical trial options for cancer patients. When tissue biopsies are unavailable, CGP from liquid biopsy may provide helpful information about a tumour's genomic make-up. CGP using tissue and liquid biopsy together may reveal more insights into a tumour's composition.
04
Continuously Evolving
Comprehensive genomic profiling can help you keep up to date with the most recent treatment options available throughout the patient’s treatment journey.
Enable precision medicine with multimodal comprehensive genomic profiling
Driven by targeted molecular therapies and immunotherapies, precision medicine offers an individualized approach that battles cancer at its core — the genome. As new oncogenic drivers are uncovered at an unprecedented rate, a testing method that can keep pace is needed. One method meeting this challenge is comprehensive genomic profiling, or CGP.
PreciseDX™ analyzes hundreds of clinically actionable biomarkers across DNA and RNA, including SNVs, CNVs, indels, fusions, and splice variants. With integrated TMB and MSI assessment, it delivers a holistic molecular profile from a single biopsy, reducing the need for multiple sequential tests and enabling smarter, faster treatment decisions.
Actionable Insights that Drive Outcomes
Beyond speed, PreciseDX™ provides clinically relevant, actionable results that can open doors to targeted therapies, immunotherapies, and clinical trials. With CGP, clinicians can maximize treatment opportunities, improve patient matching, and support better outcomes, including higher response rates, longer progression-free survival, and improved overall survival.
Any Questions
Transform Cancer Care with Precision Medicine
Our comprehensive genomic profiling tests provide information about clinically relevant biomarkers and genomic alterations to help match patients to approved targeted therapies, immunotherapies, and clinical trial options — giving physicians and patients powerful actionable insights for navigating cancer care.